GLPwatch
Tirzepatide
Approved · GIP and GLP-1 receptor dual agonist
Last updated 2026-05-28Tirzepatide is a dual-action drug that works by activating two natural hormones in the body, GIP and GLP-1, which help control blood sugar and appetite. It is sold under the brand names Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea.
AI summary of the sources below.
| Mechanism | GIP and GLP-1 receptor dual agonist Mimics two gut hormones, GIP and GLP-1, which together lower blood sugar and reduce appetite. |
|---|---|
| Status | Approved |
| Branded products | mounjaro, zepbound |
| Manufacturer(s) | eli-lilly |
How Tirzepatide connects
- Products MounjaroZepbound
- Treats Type 2 diabetesObesityObstructive sleep apnea
- Maker Eli Lilly
- Trials 164 trials
- Research 650 papers
Trials (164)
- A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese
- Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer
- Tirzepatide for Obesity and Meth Use Disorder
- Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV
- Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT)
- A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide
- A Study of Tirzepatide (LY3298176) in Healthy Lactating Females
- A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity
- Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure
- A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)
- Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
- A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus
- A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices
- Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
- Efficacy and Safety of Tirzepatide for Weight Management
- A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin
- Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart Disease
- Tirzepatide Use in People With Obesity and Type 1 Diabetes
- A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
- Tirzepatide in PWS, HO and GNSO
- A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
- A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide
- A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes
- A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes
- Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over
Top research (650)
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
- Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
- Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.
- Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
- Tirzepatide for Obesity Treatment and Diabetes Prevention.
- Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
- Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.
- Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.
- Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.
- Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
- Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.
- Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
- GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice.